

Melissa M Damschroder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2133036/publications.pdf>

Version: 2024-02-01

38
papers

2,562
citations

257357

24
h-index

302012

39
g-index

39
all docs

39
docs citations

39
times ranked

3905
citing authors

#	ARTICLE	IF	CITATIONS
1	MEDI-563, a humanized anti-IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 1344-1353.e2.	1.5	481
2	Targeting CD73 in the tumor microenvironment with MEDI9447. <i>Oncotarget</i> , 2016, 5, e1208875.	2.1	221
3	Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms. <i>Journal of Biological Chemistry</i> , 2014, 289, 7812-7824.	1.6	187
4	Assessment of an Anti-Alpha-Toxin Monoclonal Antibody for Prevention and Treatment of Staphylococcus aureus-Induced Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1108-1117.	1.4	154
5	Modulation of the Effector Functions of a Human IgG1 through Engineering of Its Hinge Region. <i>Journal of Immunology</i> , 2006, 177, 1129-1138.	0.4	126
6	Current approaches to fine mapping of antigen-antibody interactions. <i>Immunology</i> , 2014, 142, 526-535.	2.0	121
7	B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 213-222.	1.3	119
8	Molecular basis for antagonistic activity of anifrolumab, an anti-interferon γ receptor 1 antibody. <i>MAbs</i> , 2015, 7, 428-439.	2.6	99
9	Structural characterization of a human Fc fragment engineered for extended serum half-life. <i>Molecular Immunology</i> , 2009, 46, 1750-1755.	1.0	93
10	Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action. <i>MAbs</i> , 2016, 8, 454-467.	2.6	91
11	Direct targeting of $\alpha_3\beta_1$ integrin on tumor cells with a monoclonal antibody, Abegrin, α . <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3122-3129.	1.9	89
12	Structural characterization of a mutated, ADCC-enhanced human Fc fragment. <i>Molecular Immunology</i> , 2008, 45, 1872-1882.	1.0	81
13	Mechanisms of Neutralization of a Human Anti-IL-5 toxin Antibody. <i>Journal of Biological Chemistry</i> , 2014, 289, 29874-29880.	1.6	74
14	Antibody humanization by framework shuffling. <i>Methods</i> , 2005, 36, 43-60.	1.9	60
15	Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools. <i>Molecular Pharmaceutics</i> , 2018, 15, 5697-5710.	2.3	52
16	Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineering. <i>MAbs</i> , 2016, 8, 941-950.	2.6	51
17	MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1650-1660.	1.9	50
18	Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody. <i>Journal of Biological Chemistry</i> , 2018, 293, 8439-8448.	1.6	50

#	ARTICLE	IF	CITATIONS
19	A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1637-1649.	1.9	45
20	Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties. <i>Molecular Immunology</i> , 2007, 44, 3049-3060.	1.0	38
21	Antibody-Dependent Cell-Mediated Cytotoxicity Effector-Enhanced EphA2 Agonist Monoclonal Antibody Demonstrates Potent Activity against Human Tumors. <i>Neoplasia</i> , 2009, 11, 509-IN2.	2.3	35
22	Experimentally guided computational antibody affinity maturation with de novo docking, modelling and rational design. <i>PLoS Computational Biology</i> , 2019, 15, e1006980.	1.5	35
23	Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1024-1038.	1.9	31
24	The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA. <i>PLoS ONE</i> , 2012, 7, e36412.	1.1	28
25	Structural and Functional Characterization of an Agonistic Anti-Human EphA2 Monoclonal Antibody. <i>Journal of Molecular Biology</i> , 2011, 413, 390-405.	2.0	23
26	Molecular basis for the mechanism of action of an anti-TACE antibody. <i>MAbs</i> , 2016, 8, 1598-1605.	2.6	23
27	Molecular basis for the antagonistic activity of an anti-CXCR4 antibody. <i>MAbs</i> , 2016, 8, 163-175.	2.6	20
28	Process optimization and protein engineering mitigated manufacturing challenges of a monoclonal antibody with liquid-liquid phase separation issue by disrupting inter-molecule electrostatic interactions. <i>MAbs</i> , 2019, 11, 789-802.	2.6	16
29	Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	16
30	Generation and Characterization of an IgG4 Monomeric Fc Platform. <i>PLoS ONE</i> , 2016, 11, e0160345.	1.1	14
31	Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies. <i>Molecular Immunology</i> , 2004, 41, 985-1000.	1.0	11
32	Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non-small-cell lung carcinoma and rodent tumor models. <i>PLoS ONE</i> , 2020, 15, e0234268.	1.1	7
33	Discovery and characterization of potent IL-21 neutralizing antibodies via a novel alternating antigen immunization and humanization strategy. <i>PLoS ONE</i> , 2019, 14, e0211236.	1.1	6
34	Crystallization and preliminary X-ray diffraction analysis of the complex of a human anti-ephrin type-A receptor 2 antibody fragment and its cognate antigen. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2010, 66, 730-733.	0.7	5
35	Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-interferon antibody fragment and human interferon β -2A. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2009, 65, 14-16.	0.7	3
36	Bi-Epitope SPR Surfaces: A Solution to Develop Robust Immunoassays. <i>PLoS ONE</i> , 2014, 9, e112070.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Long-acting antibody ligand mimetics for HER4-selective agonism. <i>Scientific Reports</i> , 2020, 10, 17257.	1.6	2
38	In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance. <i>Communications Biology</i> , 2021, 4, 1048.	2.0	1